BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 9516935)

  • 1. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
    Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
    Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
    Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
    Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
    Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study.
    Liu KZ; Schultz CP; Mohammad RM; Al-Katib AM; Johnston JB; Mantsch HH
    Cancer Lett; 1998 May; 127(1-2):185-93. PubMed ID: 9619876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
    Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
    Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.
    Beck FW; Eilender DS; Dandashi MH; Siddiq F; Snell DC; Godmere MA; Al-Katib AM; Mohammad RM
    Int J Mol Med; 2004 Jul; 14(1):113-9. PubMed ID: 15202025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.
    Wall NR; Beck FW; Al-Katib AM; Mohammad RM
    J Drug Target; 2001; 9(5):329-39. PubMed ID: 11770703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line.
    Liu KZ; Schultz CP; Johnston JB; Beck FW; Al-Katib AM; Mohammad RM; Mantsch HH
    Leukemia; 1999 Aug; 13(8):1273-80. PubMed ID: 10450757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM
    Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
    Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
    Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
    Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia.
    Begleiter A; Wang H; Verburg L; Lee K; Israels LG; Mowat MR; Johnston JB
    Leukemia; 1996 Dec; 10(12):1959-65. PubMed ID: 8946937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
    Beck FW; Al-Katib AM; Ahmad I; Wall NR; Liu KZ; Mantsch HH; Mohammad RM
    Int J Mol Med; 2000 Apr; 5(4):341-7. PubMed ID: 10719048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.
    al-Katib A; Mohammad RM; Dan M; Hussein ME; Akhtar A; Pettit GR; Sensenbrenner LL
    Exp Hematol; 1993 Jan; 21(1):61-5. PubMed ID: 8093352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.
    Mohammad RM; Mohamed AN; Hamdan MY; Vo T; Chen B; Katato K; Abubakr YA; Dugan MC; al-Katib A
    Leukemia; 1996 Jan; 10(1):130-7. PubMed ID: 8558918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
    Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.